219 related articles for article (PubMed ID: 33177818)
1. Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.
Valipour A; Shah PL; Herth FJ; Pison C; Schumann C; Hübner RH; Bonta PI; Kessler R; Gesierich W; Darwiche K; Lamprecht B; Perez T; Skowasch D; Deslee G; Marceau A; Sciurba FC; Gosens R; Hartman JE; Conway F; Duller M; Mayse M; Norman HS; Slebos DJ;
Int J Chron Obstruct Pulmon Dis; 2020; 15():2807-2816. PubMed ID: 33177818
[TBL] [Abstract][Full Text] [Related]
2. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes.
Pison C; Shah PL; Slebos DJ; Ninane V; Janssens W; Perez T; Kessler R; Deslee G; Garner JL; Hartman JE; Degano B; Mayr A; Mayse M; Peterson AD; Valipour A
Respir Res; 2021 Feb; 22(1):62. PubMed ID: 33608007
[TBL] [Abstract][Full Text] [Related]
3. Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3).
Slebos DJ; Degano B; Valipour A; Shah PL; Deslée G; Sciurba FC;
BMC Pulm Med; 2020 Feb; 20(1):41. PubMed ID: 32054473
[TBL] [Abstract][Full Text] [Related]
4. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial.
Slebos DJ; Shah PL; Herth FJF; Pison C; Schumann C; Hübner RH; Bonta PI; Kessler R; Gesierich W; Darwiche K; Lamprecht B; Perez T; Skowasch D; Deslee G; Marceau A; Sciurba FC; Gosens R; Hartman JE; Srikanthan K; Duller M; Valipour A;
Am J Respir Crit Care Med; 2019 Dec; 200(12):1477-1486. PubMed ID: 31404499
[No Abstract] [Full Text] [Related]
5. Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2.
Conway F; Tonkin J; Valipour A; Pison C; Schumann C; Bonta PI; Kessler R; Gesierich W; Darwiche K; Lamprecht B; Skowasch D; Johnson PJ; Slebos DJ; Shah PL;
Respiration; 2022; 101(11):1069-1074. PubMed ID: 36302345
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of bilateral targeted lung denervation in patients with COPD.
Valipour A; Asadi S; Pison C; Jondot M; Kessler R; Benneddif K; Deslee G; Verdier M; Slebos DJ; Mayse M
Int J Chron Obstruct Pulmon Dis; 2018; 13():2163-2172. PubMed ID: 30038492
[TBL] [Abstract][Full Text] [Related]
7. Targeted lung denervation for moderate to severe COPD: a pilot study.
Slebos DJ; Klooster K; Koegelenberg CF; Theron J; Styen D; Valipour A; Mayse M; Bolliger CT
Thorax; 2015 May; 70(5):411-9. PubMed ID: 25739911
[TBL] [Abstract][Full Text] [Related]
8. Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients.
Valipour A; Shah PL; Pison C; Ninane V; Janssens W; Perez T; Kessler R; Deslee G; Garner J; Abele C; Hartman JE; Slebos DJ;
Respiration; 2019; 98(4):329-339. PubMed ID: 31220851
[TBL] [Abstract][Full Text] [Related]
9. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV
Chai CS; Ng DL; Bt Mos S; Ibrahim MAB; Tan SB; Pang YK; Liam CK
BMC Pulm Med; 2023 Apr; 23(1):150. PubMed ID: 37118725
[TBL] [Abstract][Full Text] [Related]
10. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.
Watz H; Tetzlaff K; Magnussen H; Mueller A; Rodriguez-Roisin R; Wouters EFM; Vogelmeier C; Calverley PMA
Respir Res; 2018 Dec; 19(1):251. PubMed ID: 30545350
[TBL] [Abstract][Full Text] [Related]
11. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
12. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease.
Howcroft M; Walters EH; Wood-Baker R; Walters JA
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD005074. PubMed ID: 27990628
[TBL] [Abstract][Full Text] [Related]
13. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
[TBL] [Abstract][Full Text] [Related]
14. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
[TBL] [Abstract][Full Text] [Related]
15. Physiologic and histopathologic effects of targeted lung denervation in an animal model.
Hummel JP; Mayse ML; Dimmer S; Johnson PJ
J Appl Physiol (1985); 2019 Jan; 126(1):67-76. PubMed ID: 30359539
[TBL] [Abstract][Full Text] [Related]
16. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
17. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
18. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.
Dransfield MT; Kunisaki KM; Strand MJ; Anzueto A; Bhatt SP; Bowler RP; Criner GJ; Curtis JL; Hanania NA; Nath H; Putcha N; Roark SE; Wan ES; Washko GR; Wells JM; Wendt CH; Make BJ;
Am J Respir Crit Care Med; 2017 Feb; 195(3):324-330. PubMed ID: 27556408
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
[TBL] [Abstract][Full Text] [Related]
20. Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis.
Guo J; Chen Y; Zhang W; Tong S; Dong J
Int J Surg; 2020 Jun; 78():28-35. PubMed ID: 32304896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
